{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:08:27Z","timestamp":1793678907020,"version":"4.5.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-02251-0","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T01:07:12Z","timestamp":1747444032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitors"],"prefix":"10.1038","volume":"15","author":[{"given":"Augustin","family":"Boudoussier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iban","family":"Larrouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Henrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Veillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bardel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Chautemps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charline","family":"Caumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Schilfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Duruisseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Zysman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"issue":"2","key":"2251_CR1","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1183\/09031936.00144208","volume":"34","author":"RP Young","year":"2009","unstructured":"Young, R. P. et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur. Respir J. 34 (2), 380\u2013386 (2009).","journal-title":"Eur. Respir J."},{"issue":"4","key":"2251_CR2","first-page":"265","volume":"81","author":"IM Adcock","year":"2011","unstructured":"Adcock, I. M., Caramori, G. & Barnes, P. J. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respir Int. Rev. Thorac. Dis. 81 (4), 265\u2013284 (2011).","journal-title":"Respir Int. Rev. Thorac. Dis."},{"issue":"11","key":"2251_CR3","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","volume":"3","author":"CD Mathers","year":"2006","unstructured":"Mathers, C. D. & Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3 (11), e442 (2006).","journal-title":"PLoS Med."},{"issue":"19","key":"2251_CR4","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl. J. Med. 375 (19), 1823\u20131833 (2016).","journal-title":"N Engl. J. Med."},{"issue":"54","key":"2251_CR5","doi-asserted-by":"publisher","first-page":"93149","DOI":"10.18632\/oncotarget.18703","volume":"8","author":"JH Kim","year":"2017","unstructured":"Kim, J. H., Kim, H. S. & Kim, B. J. Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Oncotarget 8 (54), 93149\u201393155 (2017).","journal-title":"Oncotarget"},{"issue":"17","key":"2251_CR6","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl. J. Med. 373 (17), 1627\u20131639 (2015).","journal-title":"N Engl. J. Med."},{"issue":"7","key":"2251_CR7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1164\/rccm.201706-1110OC","volume":"198","author":"J Biton","year":"2018","unstructured":"Biton, J. et al. Impaired tumor-infiltrating T cells in patients with chronic obstructive pulmonary disease impact lung cancer response to PD-1 Blockade. Am. J. Respir Crit. Care Med. 198 (7), 928\u2013940 (2018).","journal-title":"Am. J. Respir Crit. Care Med."},{"issue":"3","key":"2251_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1164\/rccm.201704-0795OC","volume":"197","author":"NM Mark","year":"2018","unstructured":"Mark, N. M. et al. Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non-small cell lung cancer. Am. J. Respir Crit. Care Med. 197 (3), 325\u2013336 (2018).","journal-title":"Am. J. Respir Crit. Care Med."},{"issue":"5","key":"2251_CR9","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.21037\/tlcr-21-214","volume":"10","author":"J Zhou","year":"2021","unstructured":"Zhou, J. et al. Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors. Transl Lung Cancer Res. 10 (5), 2148\u20132162 (2021).","journal-title":"Transl Lung Cancer Res."},{"issue":"9","key":"2251_CR10","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1002\/ijc.32235","volume":"145","author":"SH Shin","year":"2019","unstructured":"Shin, S. H. et al. Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. Int. J. Cancer. 145 (9), 2433\u20132439 (2019).","journal-title":"Int. J. Cancer"},{"issue":"4","key":"2251_CR11","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1164\/rccm.202008-3328PP","volume":"203","author":"MK Han","year":"2021","unstructured":"Han, M. K. et al. From GOLD 0 to pre-COPD. Am. J. Respir Crit. Care Med. 203 (4), 414\u2013423 (2021).","journal-title":"Am. J. Respir Crit. Care Med."},{"issue":"4","key":"2251_CR12","doi-asserted-by":"publisher","first-page":"2300239","DOI":"10.1183\/13993003.00239-2023","volume":"61","author":"A Agust\u00ed","year":"2023","unstructured":"Agust\u00ed, A. et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Eur. Respir J. 61 (4), 2300239 (2023).","journal-title":"Eur. Respir J."},{"issue":"21","key":"2251_CR13","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl. J. Med. 372 (21), 2018\u20132028 (2015).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"2251_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12967-017-1168-x","volume":"15","author":"H-X Zhu","year":"2017","unstructured":"Zhu, H-X. et al. Myocyte enhancer factor 2D provides a cross-talk between chronic inflammation and lung cancer. J. Transl Med. 15 (1), 65 (2017).","journal-title":"J. Transl Med."},{"issue":"1","key":"2251_CR15","doi-asserted-by":"publisher","first-page":"22402","DOI":"10.1038\/s41598-022-26650-9","volume":"12","author":"F Polverino","year":"2022","unstructured":"Polverino, F. et al. Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer. Sci. Rep. 12 (1), 22402 (2022).","journal-title":"Sci. Rep."},{"issue":"1","key":"2251_CR16","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1371\/journal.pmed.0010008","volume":"1","author":"S Grumelli","year":"2004","unstructured":"Grumelli, S. et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med. 1 (1), e8 (2004).","journal-title":"PLoS Med."},{"issue":"22","key":"2251_CR17","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl. J. Med. 378 (22), 2078\u20132092 (2018).","journal-title":"N Engl. J. Med."},{"issue":"10066","key":"2251_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389 (10066), 255\u2013265 (2017).","journal-title":"Lancet"},{"issue":"21","key":"2251_CR19","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde, P. M. et al. Neoadjuvant PD-1 Blockade in resectable lung cancer. N Engl. J. Med. 378 (21), 1976\u20131986 (2018).","journal-title":"N Engl. J. Med."},{"issue":"3","key":"2251_CR20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1164\/rccm.202107-1663SO","volume":"205","author":"FJ Martinez","year":"2022","unstructured":"Martinez, F. J. et al. Treatment trials in young patients with chronic obstructive pulmonary disease and pre-chronic obstructive pulmonary disease patients: time to move forward. Am. J. Respir Crit. Care Med. 205 (3), 275\u2013287 (2022).","journal-title":"Am. J. Respir Crit. Care Med."},{"issue":"1","key":"2251_CR21","doi-asserted-by":"publisher","first-page":"8881","DOI":"10.1038\/s41598-022-13131-2","volume":"12","author":"Y Noda","year":"2022","unstructured":"Noda, Y. et al. Quantitative evaluation of emphysema for predicting immunotherapy response in patients with advanced non-small-cell lung cancer. Sci. Rep. 12 (1), 8881 (2022).","journal-title":"Sci. Rep."},{"issue":"Supplement 1","key":"2251_CR22","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1097\/01.mcp.0000410744.75216.d0","volume":"17","author":"A Corsonello","year":"2011","unstructured":"Corsonello, A. et al. Comorbidities of chronic obstructive pulmonary disease. Curr. Opin. Pulm Med. 17 (Supplement 1), S21\u2013S28 (2011).","journal-title":"Curr. Opin. Pulm Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02251-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02251-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02251-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T01:07:13Z","timestamp":1747444033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02251-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2251"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-02251-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17145"}}